Christopher Lai

Christopher is a seasoned venture capital investor with over a decade of experience in technology investment and venture building. He co-founded The March Group and leads all investments at the firm; and is active as a board member working closely with TMF portfolio companies.

Christopher is a recognized thought leader in VC/PE (Forbes 30 under 30 Asia, Trusted Insight Top 30 Family Office Rising Stars) and is a founding VC member and mentor of the Hong Kong University of Science and Technology Advanced Venture Capital course. Prior to The March Group, Chris was the Director of Consumer and Retail Technologies at Horizons Ventures, the private investment arm of Mr. Li Ka Shing, and invested across the technology landscape globally and led investment in the US, Canada, Israel, France and China. He previously served as a member of the Board of Director at Agua Brands, Algama, Apollonia Health, Endless West, Bevi, Celsius (NASDAQ:CELH; as co-Chairman), Perfect Day, and QiFeng. A Hong Kong native, Chris studied and worked extensively abroad spanning corporate finance and M&A (at Mooreland Partners – now part of Stifel Financial Corp. NYSE:SF), and biotech corporate and business development (at IRX Therapeutics - acquired by Brooklyn ImmunoTherapeutics).

Christopher holds B.A. degrees in Neuroscience and Behavior, Genetics, and Economics from Columbia University.